How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Percutaneous insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock

    Closed for comments This consultation ended on at   Request commenting lead permission

    1 Recommendation

    1.1

    Percutaneous insertion of a catheter-based intravascular microaxial flow pump can be used in the NHS during the evidence generation period as an option to manage cardiogenic shock. There must be enhanced informed consent and auditing of outcomes.

    What this means in practice

    There are uncertainties around the safety and efficacy of this procedure. It can be used if needed while more evidence is generated to check if it is safe and clinically effective.

    After this, NICE will review this guidance and the recommendation may change.

    Healthcare professionals do not have to offer this procedure and should always discuss the available options with the person with cardiogenic shock (and their family and carers as appropriate) before a joint decision is made, if possible.

    Hospital trusts will have their own policies on funding procedures and monitoring results. NHS England may also have policies on funding of procedures.

    Enhanced informed consent

    Because there are uncertainties about whether this procedure is safe and effective, there must be an emphasis on informed consent. Healthcare professionals must make sure that people (and their families and carers as appropriate) understand the uncertainty and lack of evidence around a procedure's safety and efficacy using NICE's advice on shared decision making and NICE's information for the public. Healthcare professionals must also inform the clinical governance leads in their organisation if they want to do the procedure.

    Auditing of outcomes

    Healthcare professionals doing this procedure should collect data on safety and outcomes of the procedure and enter details about everyone having this procedure into an appropriate registry. If there is no data collection method already available, use NICE's interventional procedure outcomes audit tool and regularly review the data on outcomes and safety.

    Who should be involved with the procedure

    Patient selection should be done by a multidisciplinary team. This procedure should only be done in centres that specialise in managing cardiogenic shock and by healthcare professionals with specific training in this procedure.

    What evidence generation is needed

    Healthcare professionals must collect data specifically around the safety and efficacy of this procedure. This includes information on:

    • patient selection

    • the technique used, including device and access site

    • short- and long-term complication rates

    • short- and long-term survival outcomes

    • quality of life.

    Why the committee made this recommendation

    Results from a high-quality randomised controlled trial suggest that this procedure improves survival compared with standard care alone in a subgroup of people with cardiogenic shock associated with heart attack. There is evidence from several large retrospective observational studies, but the trial populations in these varied and the results on efficacy are inconsistent.

    The evidence shows that the procedure may be associated with complications such as bleeding, which can be serious. But because there are limited treatment options for people with cardiogenic shock, the procedure can be used as an option in the NHS while more evidence is generated.